A novel bispecific antibody against CD38 (CD38 Bsp.) and DOTA-biotin eradicates NHL and multiple myeloma (MM) tumors in murine models. In this pretargeted approach, the CD38 or CD20 control Bsp. was injected IV first. After tumor targeting and clearance from the circulation, ⁹⁰Y-DOTA-biotin was injected IV and pharmacokinetic studies were carried out to calculate tumor and normal tissue dosimetry, and survival of mice was monitored. (A) Tumor and normal tissue dosimetry in CD38 Bsp. Namalwa NHL model. (B) Survival of mice bearing Namalwa NHL tumors administered CD38 or CD20 control Bsp. and ⁹⁰Y-DOTA-biotin. (C) Survival of mice bearing H929 MM tumors and administered CD38 or CD20 control Bsp. and ⁹⁰Y-DOTA-biotin. The figure has been adapted from Figures 4, 5B, and 6B in the article by Green et al that begins on page 611.